glp 1 oral medication for weight loss GLP-1s Loss: What You Need to Know No injections Decoding GLP-1 Weight Loss Medications

To make firmer conclusions, additional clinical trials designed around revealing cardiovascular benefits should be conducted

Benson et al

In 2022, around 44% of women were overweight, and 18% were obese [1]

However, tolerability, discontinuation rates, and comparative efficacy will be key watchpoints

While enzymatic DPP-4 may be more closely related to obesity-associated inflammation and glucose regulation, soluble DPP-4 may have a distinct role that is not associated with inflammation

Semaglutide (Ozempic, Wegovy) Tirzepatide (Mounjaro, Zepbound) Liraglutide (Victoza) Clinical Studies A February 2026 study found that SGLT2 inhibitors are often associated with a lower 5-year risk of chronic kidney disease progression than GLP-1s, though both offer substantial benefits